HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 1082-1085

  Patanè, Salvatore ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

Cancer chemotherapy; Cardio oncology; Cardiotoxicity; HERG; Multidrug resistance (MDR); Torsade de pointes arrhythmia(TdP)

Indexed keywords

CARDIOVASCULAR AGENT; ERG1 POTASSIUM CHANNEL; MULTIDRUG RESISTANCE PROTEIN; POTASSIUM CHANNEL HERG;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASMS;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR SYSTEM; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 84908200656     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.129     Document Type: Article

References (127)

1. E. Conti, A. Romiti, and M.B. Musumeci Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors Int J Cardiol 167 6 Sep 10 2013 2421 2429
2. S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, and M. Nicolae Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int J Cardiol 172 2 Mar 15 2014 e331 e333
3. S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, and Y. Kihara Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients Int J Cardiol 167 5 Sep 1 2013 2335 2337
4. J.M. Scott, L.W. Jones, and W.E. Hornsby Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training Int J Cardiol 171 2 Feb 1 2014 e50 e51
5. S. Claridge, A. Chakrabarti, K. Greaves, and C.J. Boos Successful use of trastuzumab following cardiac resynchronisation therapy Int J Cardiol 166 2 Jun 20 2013 e33 e34
6. M. Lotrionte, G. Palazzoni, and A. Abbate Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (liposomal doxorubicin-investigational chemotherapy-tissue doppler imaging evaluation) randomized pilot study Int J Cardiol 167 3 Aug 10 2013 1055 1057
7. M.G. Kaya, M. Ozkan, and O. Gunebakmaz Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 167 5 Sep 1 2013 2306 2310
8. K.L. Wang, C.J. Liu, and T.F. Chao Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis Int J Cardiol 167 5 Sep 1 2013 2162 2166
9. Y.F. Hu, C.J. Liu, and P.M. Chang Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients Int J Cardiol 165 2 May 10 2013 355 357
10. A. Budaj-Fidecka, M. Kurzyna, and A. Fijałkowska In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL Registry data Int J Cardiol 168 4 Oct 9 2013 3543 3549
11. P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, and S. Patanè Contrast-enhancing right atrial thrombus in cancer patient Int J Cardiol 173 3 May 15 2014 e35 e37
12. S. Grover, D.P. Leong, and A. Chakrabarty Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers Int J Cardiol 168 6 Oct 15 2013 5465 5467
13. W. Jurczak, S. Szmit, and M. Sobociński Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study Int J Cardiol 168 6 Oct 15 2013 5212 5217
14. C. Lestuzzi Cardioncology, oncocardiology. Are we barking up the wrong tree? Int J Cardiol 167 2 Jul 31 2013 307 309
15. P. Pugliatti, R. Donato, C. Zito, S. Carerj, and S. Patanè Cardio inhibitory vasovagal syncope in a cancer patient Int J Cardiol 174 2 Jun 15 2014 e64 e65
16. P. Pugliatti, C. De Gregorio, and S. Patanè The chance finding of echocardiographic complications of infective endocarditis Int J Cardiol 161 3 Nov 29 2012 e50 e51
17. S. Patanè, F. Marte, M. Sturiale, and G. Dattilo ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses Int J Cardiol 148 2 Apr 14 2011 e31 e33
18. Y. Elkina, S. Palus, and A. Tschirner Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia Int J Cardiol 170 2 Dec 10 2013 160 166
19. J. Springer, A. Tschirner, K. Hartman, S. von Haehling, S.D. Anker, and W. Doehner The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy Int J Cardiol 168 4 Oct 9 2013 3527 3531
20. S. Palus, S. von Haehling, and V.C. Flach Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia Int J Cardiol 168 4 Oct 9 2013 3412 3418
21. V. Avbelj, and R. Trobec A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope Int J Cardiol 166 3 Jul 1 2013 e59 e61
22. W.J. Jang, H.R. Yim, S.H. Lee, S.J. Park, J.S. Kim, and Y.K. On Prognosis after tilt training in patients with recurrent vasovagal syncope Int J Cardiol 168 4 Oct 9 2013 4264 4265
23. K.P. Loh, and O. Ogunneye Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! Int J Cardiol 164 3 Apr 15 2013 e38 e39
24. S. Patanè, and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur Heart J 30 10 May 2009 1169 1170
25. M. Arcopinto, C.A. Cella, and R. Wesolowski Primary prevention of cancer-related thrombosis: special focus on ambulatory patients Int J Cardiol 173 3 May 15 2014 583 584
26. S. Patanè Insights into Cardio-oncology: Adrenergic receptor signaling and pathways in breast cancer Curr Med Res Opin 26 Jun 2014 1 2
27. R.A. Hong, T. Iimura, K.N. Sumida, and R.M. Eager Cardio-oncology/onco-cardiology Clin Cardiol 33 12 Dec 2010 733 737
28. S. Patanè, and F. Marte Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol 146 1 Jan 7 2011 e20 e22
29. S. Patanè, and F. Marte Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario Int J Cardiol 134 3 May 29 2009 e147 e149
30. S. Patanè Prostate-specific antigen kallikrein and the heart World J Cardiol 1 1 Dec 31 2009 23 25
31. S. Patanè Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies J Card Fail 20 6 Jun 2014 456 457
32. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res 7 3 Apr 2014 369 371
33. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy? J Cardiovasc Transl Res 7 3 Apr 2014 372 374
34. S. Patanè A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis Int J Cardiol 157 3 Jun 14 2012 448 449
35. S. Patanè Cardiotoxicity: cisplatin and long term cancer survivors Int J Cardiol 175 1 Jul 15 2014 201 202
36. S. Patanè A challenge in cardiology: the oncosurgery Int J Cardiol 174 2 Jun 15 2014 411 412
37. T.M. Suter, and M.S. Ewer Cancer drugs and the heart: importance and management Eur Heart J 34 15 Apr 2013 1102 1111
38. +channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells PLoS One 9 2 Feb 6 2014 e88164
39. K.R. Doherty, R.L. Wappel, and D.R. Talbert Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes Toxicol Appl Pharmacol 272 1 Oct 1 2013 245 255
40. N.S. Narayana Moorthy, M.J. Ramos, and P.A. Fernandes Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design Curr Drug Targets 14 1 Jan 1 2013 102 113
41. J. Heijman, N. Voigt, L.G. Carlsson, and D. Dobrev Cardiac safety assays Curr Opin Pharmacol 15C Apr 2014 16 21
42. H. Shan, Y. Zhang, and B. Cai Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling Int J Cardiol 167 6 Sep 10 2013 2798 2805
43. P.M. Rautaharju, J.W. Mason, and T. Akiyama New age- and sex-specific criteria for QT prolongation based on rate correction formulas that minimize bias at the upper normal limits Int J Cardiol 174 3 Jul 1 2014 535 540
44. S. Peters, and H.U. Klein Life-threatening ventricular arrhythmias due to atypical mid-ventricular tako tsubo cardiomyopathy in a patient with chronic QT interval prolongation under anti-psychotic medication Int J Cardiol 172 3 Apr 1 2014 e534 e536
45. M. Tarapués, G. Cereza, A.L. Arellano, E. Montané, and A. Figueras Serious QT interval prolongation with ranolazine and amiodarone Int J Cardiol 172 1 Mar 1 2014 e60 e61
46. H.L. Nguyen, G.H. Pieper, and R. Wilders Andersen-Tawil syndrome: clinical and molecular aspects Int J Cardiol 170 1 Dec 5 2013 1 16
47. J. Bennett, B. Ferdinande, and P. Kayaert Time course of electrocardiographic changes in transient left ventricular ballooning syndrome Int J Cardiol 169 4 Nov 15 2013 276 280
48. D. Ma, H. Wei, and Y. Zhao Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells Int J Cardiol 168 6 Oct 15 2013 5277 5286
49. E. Park, J. Willard, D. Bi, M. Fiszman, D. Kozeli, and J. Koerner The impact of drug-related QT prolongation on FDA regulatory decisions Int J Cardiol 168 5 Oct 12 2013 4975 4976
50. S. Koppikar, A. Baranchuk, J.C. Guzmán, and C.A. Morillo Stroke and ventricular arrhythmias Int J Cardiol 168 2 Sep 30 2013 653 659
51. H.Y. Chang, W.H. Yin, and L.W. Lo The utilization of twelve-lead electrocardiography for predicting sudden cardiac death after heart transplantation Int J Cardiol 168 3 Oct 3 2013 2665 2672
52. S. Møller, J.D. Hove, U. Dixen, and F. Bendtsen New insights into cirrhotic cardiomyopathy Int J Cardiol 167 4 Aug 20 2013 1101 1108
53. A.H. Katsanos, P. Korantzopoulos, G. Tsivgoulis, A.P. Kyritsis, M. Kosmidou, and S. Giannopoulos Electrocardiographic abnormalities and cardiac arrhythmias in structural brain lesions Int J Cardiol 167 2 Jul 31 2013 328 334
54. R. La Rocca, A. Foschi, N.M. Preston, C. Ceriani, V. Materia, and S. Patanè QT interval prolongation and bradycardia in lithium-induced nephrogenic diabetes insipidus Int J Cardiol 162 1 Dec 15 2012 e1 e2
55. J.D. Rich, T. Thenappan, and B. Freed QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension Int J Cardiol 167 3 Aug 10 2013 669 676
56. T. Inoue, T. Doi, and K. Beppu Warning to "Refeeding syndrome". Torsades de pointes and ventricular tachyarrhythmia with marked QT prolongation induced by acute glucose injection: report of two cases Int J Cardiol 156 2 Apr 19 2012 222 224
57. S. Patanè Torsade de pointes, QT interval prolongation and renal disease Int J Cardiol 149 2 Jun 2 2011 241 242
58. S. Patanè, F. Marte, G. Di Bella, A. Currò, and S. Coglitore QT interval prolongation, torsade de pointes and renal disease Int J Cardiol 130 2 Nov 12 2008 e71 e73
59. F. Santoro, R. Ieva, A. Ferraretti, L. De Gennaro, M. Di Biase, and N.D. Brunetti Atrial fibrillation followed by torsade de pointes degenerated into ventricular fibrillation spontaneously terminated and restored sinus rhythm Int J Cardiol 166 3 Jul 1 2013 e39 e40
60. +channel: target and antitarget strategies in drug development Pharmacol Res 57 3 Mar 2008 181 195
61. R.M. Turner, and M. Pirmohamed Cardiovascular pharmacogenomics: expectations and practical benefits Clin Pharmacol Ther 95 3 Mar 2014 281 293
62. B.J. Drew, M.J. Ackerman, and M. Funk Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation Circulation 121 8 Mar 2 2010 1047 1060 [No abstract available]
63. Erratum Circulation 122 8 Aug 24 2010 e440
64. J.M. Brell Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy Prog Cardiovasc Dis 53 2 Sep-Oct 2010 164 172
65. L. Johannesen, J. Vicente, and R.A. Gray Improving the assessment of heart toxicity for all new drugs through translational regulatory science Clin Pharmacol Ther 95 5 May 2014 501 508
66. R. Zhang, P. Tian, and Q. Chi Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer Oncol Rep 27 2 Feb 2012 433 440
67. A. Fiore, L. Carraresi, and A. Morabito Characterization of hERG1 channel role in mouse colorectal carcinogenesis Cancer Med 2 5 Oct 2013 583 594
68. A. Dueñas-González, P. García-López, L.A. Herrera, J.L. Medina-Franco, A. González-Fierro, and M. Candelaria The prince and the pauper. A tale of anticancer targeted agents Mol Cancer 7 Oct 23 2008 82
69. S.A. Shah, G. Koyama, D. Da Costa, P. McGregor, and M. Kolasa Combination use of ranolazine with dofetilide for the maintenance of atrial fibrillation Int J Cardiol 172 3 Apr 1 2014 e428 e429
70. M. Tarapués, G. Cereza, A.L. Arellano, E. Montané, and A. Figueras Serious QT interval prolongation with ranolazine and amiodarone Int J Cardiol 172 1 Mar 1 2014 e60 e61
71. M.P. van den Berg, F. van den Heuvel, J.P. van Tintelen, P.G. Volders, and I.C. van Gelder Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazinecombined with a beta-blocker Int J Cardiol 171 1 Jan 15 2014 90 92
72. G. Savarese, G. Rosano, and C. D'Amore Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis Int J Cardiol 169 4 Nov 15 2013 262 270
73. W.C. Tsai, Y.C. Chen, Y.H. Kao, Y.Y. Lu, S.A. Chen, and Y.J. Chen Distinctive sodium and calcium regulation associated with sex differences in atrial electrophysiology of rabbits Int J Cardiol 168 5 Oct 12 2013 4658 4666
74. C.G. Tocchetti, A. Carpi, and C. Coppola Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction Eur J Heart Fail 16 4 Jan 6 2014 358 366
75. G. Minotti Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs J Pharmacol Exp Ther 346 3 Sep 2013 343 349
76. J.D. Moreno, P.C. Yang, and J.R. Bankston Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening Circ Res 113 7 Sep 13 2013 e50 e61
77. +current J Cardiovasc Pharmacol 51 6 Jun 2008 581 589
78. Z. Liu, R.B. Williams, and B.D. Rosen The potential contribution of ranolazine to Torsade de Pointe J Cardiovasc Dis Res 4 3 Sep 2013 187 190
79. M.B. Djamgoz, and R. Onkal Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic disease Recent Pat Anticancer Drug Discov 8 1 Jan 1 2013 66 84
80. J. Bilbro, M. Mart, and N. Kyprianou Therapeutic value of quinazoline-based compounds in prostate cancer Anticancer Res 33 11 Nov 2013 4695 4700
81. A. Petty, E. Myshkin, and H. Qin A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo PLoS One 7 8 2012 e42120
82. F.Z. El Sharkawi, H.A. El Shemy, and H.M. Khaled Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin Asian Pac J Cancer Prev 15 1 2014 199 203
83. G. Cao, H.G. Llambí, A. Muller, G. Ottaviano, and J. Milei Rosuvastatin increases myocardial microvessels in SHR rats. Role of thioredoxin-1 and peroxiredoxin-2 expression Int J Cardiol 174 1 Jun 1 2014 153 155
84. Y. Ishibashi, S. Nakashima, T. Matsui, and S. Yamagishi Rosuvastatin restores advanced glycation end product-induced decrease in sirtuin 1 (SIRT1) mRNA levels in THP-1 monocytic cells through its anti-oxidative properties Int J Cardiol 169 6 Nov 30 2013 e102 e103
85. M. Gliozzi, R. Walker, and S. Muscoli Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia Int J Cardiol 170 2 Dec 10 2013 140 145
86. D. Tziakas, G. Chalikias, and A. Kapelouzou Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: modulatory effects of rosuvastatin Int J Cardiol 170 2 Dec 10 2013 173 181
87. B. Wu, Z. Su, R. Lin, R. Dai, C. Chen, and H. Wu Short-time pretreatment of rosuvastatin attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression Int J Cardiol 168 5 Oct 12 2013 4946 4948
88. G. Sardella, L. Lucisano, and M. Mancone Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial Int J Cardiol 168 4 Oct 9 2013 3715 3720
89. M. Hu, S.S. Lui, G.T. Ko, and B. Tomlinson Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies Int J Cardiol 168 3 Oct 3 2013 3071 3073
90. J. Luo, J. Li, and X. Shen The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome Int J Cardiol 167 5 Sep 1 2013 2350 2353
91. T. Liu, P. Korantzopoulos, L. Li, and G. Li Preventive effects of rosuvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials Int J Cardiol 167 6 Sep 10 2013 3058 3060
92. G. Savarese, F. Musella, M. Volpe, F. Paneni, and P. Perrone-Filardi Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis Int J Cardiol 167 6 Sep 10 2013 2482 2489
93. L.F. Pinheiro, C.N. França, and M.C. Izar Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease Int J Cardiol 158 1 Jun 28 2012 125 129
94. K.K. Koh, M.J. Quon, and I. Sakuma Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients Int J Cardiol 166 2 Jun 20 2013 509 515
95. I. Plante, P. Vigneault, B. Drolet, and J. Turgeon Rosuvastatin blocks hERG current and prolongs cardiac repolarization J Pharm Sci 101 2 Feb 2012 868 878
96. Z.Y. Wu, D.J. Yu, T.W. Soong, G.S. Dawe, and J.S. Bian Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis J Biol Chem 286 25 Jun 24 2011 22186 22194
97. A.N. Katchman, J. Koerner, T. Tosaka, R.L. Woosley, and S.N. Ebert Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs J Pharmacol Exp Ther 316 3 Mar 2006 1098 1106
98. B.A. Furst, K.M. Champion, J.M. Pierre, D.A. Wirshing, and W.C. Wirshing Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin Biol Psychiatry 51 3 Feb 1 2002 264 265
99. M. Jafari, M. Rezaei, H. Kalantari, and M. Hashemitabar Determination of cell death induced by lovastatin on human colon cell line HT29 using the comet assay Jundishapur J Nat Pharm Prod 8 4 Nov 2013 187 191
100. R.A. Siddiqui, K.A. Harvey, Z. Xu, S.K. Natarajan, and V.J. Davisson Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells Bioorg Med Chem 22 6 Mar 15 2014 1899 1908
101. C. Arias, T. González, and I. Moreno Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels Cardiovasc Res 57 3 Mar 2003 660 669
102. A.A. Paul, H.J. Witchel, and J.C. Hancox Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine Br J Pharmacol 136 5 Jul 2002 717 729
103. J. Mergenthaler, W. Haverkamp, and A. Hüttenhofer Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel Naunyn Schmiedebergs Arch Pharmacol 363 4 Apr 2001 472 480
104. H.J. Witchel, C.E. Dempsey, and R.B. Sessions The low-potency, voltage-dependent HERG blocker propafenone - molecular determinants and drug trapping Mol Pharmacol 66 5 Nov 2004 1201 1212
105. F. Klepsch, P. Chiba, and G.F. Ecker Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein PLoS Comput Biol 7 5 May 2011 e1002036
106. J. Shao, and G. Feng Selective killing effect of oxytetracycline, propafenone and metamizole on A549 or Hela cells Chin J Cancer Res 25 6 Dec 2013 662 670
107. P. Korantzopoulos, T.M. Kolettis, and A. Papathanasiou Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation Heart 92 5 May 2006 631 634
108. J.T. Hii, D.G. Wyse, A.M. Gillis, J.M. Cohen, and L.B. Mitchell Propafenone-induced torsade de pointes: cross-reactivity with quinidine Pacing Clin Electrophysiol 14 11 Pt 1 Nov 1991 1568 1570
109. M. Rosengarten, and R. Brooks Torsade de pointes ventricular tachycardia in a hypothyroid patient treated with propafenone Can J Cardiol 3 5 Jun-Aug 1987 234 239
110. N. Rehnqvist, C.G. Ericsson, S. Eriksson, G. Olsson, and G. Svensson Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarction Acta Med Scand 216 5 1984 525 530
111. S. Zhang, Z. Zhou, Q. Gong, J.C. Makielski, and C.T. January Mechanism of block and identification of the verapamil binding domain to HERG potassium channels Circ Res 84 9 May 14 1999 989 998
112. W.S. Redfern, L. Carlsson, and A.S. Davis Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc Res 58 1 Apr 1 2003 32 45
113. 2 + exchanger and l-type calcium channel block as a potential strategy to suppress arrhythmias and maintain ventricular function Circ Arrhythm Electrophysiol 6 2 Apr 2013 371 379
114. M. McCarthy, G. Auda, and S. Agrawal In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer Exp Mol Pathol 97 1 Aug 2014 6 15
115. J. Huang, T. Zhang, and K. Ma Clinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer Cancer Chemother Pharmacol 72 4 Oct 2013 889 896
116. B. Pająk, E. Kania, B. Gajkowska, and A. Orzechowski Verapamil-induced autophagy-like process in colon adenocarcinoma COLO 205 cells; the ultrastructural studies Pharmacol Rep 64 4 2012 991 996
117. Y. Chen, X.L. Zheng, and D.L. Fang Dual agent loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model Int J Mol Sci 15 2 Feb 18 2014 2761 2772
118. Q. Wan, Y.X. Chu, A. Zheng, X.J. Liu, and W.C. Wu Effects of verapamil on the proliferation and migration of cervical cancer cells Sichuan Da Xue Xue Bao Yi Xue Ban 42 1 Jan 2011 78 81
119. C. Zhang, F. Lv, L. Zhou, X. Li, X.X. Wu, and R.M. Hoffman Effect of verapamil on the expression of EGFR and NM23 in A549 human lung cancer cells Anticancer Res 29 1 Jan 2009 27 32
120. M. Tsubaki, M. Komai, and T. Itoh By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells Leuk Res 38 1 Jan 2014 121 130
121. +channels IKr and IKs Therapie 55 1 Jan-Feb 2000 195 202
122. +channels involved in long QT syndromes, are targets for calcium channel blockers Mol Pharmacol 54 4 Oct 1998 695 703
123. T. Feridooni, C. Mac Donald, D. Shao, P. Yeung, and R.U. Agu Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line Acta Pharm 63 4 Dec 2013 493 503
124. K. Kawakami, T. Nagatomo, and H. Abe Comparison of HERG channel blocking effects of various beta-blockers - implication for clinical strategy Br J Pharmacol 147 6 Mar 2006 642 652
125. M. Monami, L. Filippi, and A. Ungar Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials Curr Med Res Opin 29 4 Apr 2013 369 378
126. P.Y. Kim, and M.S. Ewer Chemotherapy and QT prolongation: overview with clinical perspective Curr Treat Options Cardiovasc Med 16 5 May 2014 303
127. S.A. Francis, S. Cheng, C.L. Arteaga, and J. Moslehi Heart failure and breast cancer therapies: moving towards personalized risk assessment J Am Heart Assoc 3 1 Feb 28 2014 e000780